TLDR:
- Annovis Bio’s buntanetap halts cognitive decline in Parkinson’s patients.
- Buntanetap reverses cognitive decline in Parkinson’s with Alzheimer’s pathology.
- Annovis Bio’s stock surges 28% on promising neurodegenerative drug data.
- Study shows buntanetap reduces neurodegeneration biomarkers in Parkinson’s.
- Annovis Bio reveals breakthrough data for Alzheimer’s, Parkinson’s treatment.
Annovis Bio, Inc. (ANVS) has seen a significant surge in stock price, rising by 28.47% recently. The stock reached a peak of $3.19 before slightly retracting.
Annovis Bio, Inc., ANVS
This boost comes after the company released promising data regarding its drug, buntanetap, for the treatment of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease.
New Data Highlights Potential of Buntanetap in Parkinson’s Patients with Alzheimer’s Pathology
Annovis Bio’s Phase 3 study of buntanetap has shown groundbreaking results in early-stage Parkinson’s patients. The treatment successfully halted cognitive decline across the overall patient population. Notably, patients with mild dementia experienced the most significant improvement.
Further analysis revealed that about 25% of the participants had amyloid co-pathology, a condition often seen in Alzheimer’s patients. These individuals displayed greater cognitive decline over the course of the study. Buntanetap effectively reversed this decline, demonstrating its potential to treat Parkinson’s patients with Alzheimer’s-related pathology.
The findings reinforce Annovis’ long-held belief that neurodegenerative diseases are often interconnected. Both Alzheimer’s and Parkinson’s involve multiple neurotoxic proteins that drive cognitive and functional decline. Addressing this complexity, buntanetap works by targeting several toxic proteins simultaneously, providing a more effective solution.
Therapeutic Impact: Cognitive Improvement and Biomarker Reductions
Buntanetap treatment also led to measurable reductions in key biomarkers of neurodegeneration, including pTau217, total tau, and brain-derived tau. These biomarkers are critical indicators of Alzheimer’s disease progression. The observed reductions signal that buntanetap is modulating the underlying drivers of cognitive deterioration.
The results of this study are seen as a significant step in treating neurodegenerative diseases. They suggest that buntanetap could benefit a broader range of patients suffering from cognitive decline. This includes those with both Alzheimer’s and Parkinson’s diseases, whose conditions often overlap.
Cheng Fang, Senior VP of Research & Development at Annovis, commented on the findings. He emphasized that these data are the first of their kind, as no other studies have explored treatment effects in Parkinson’s patients with amyloid co-pathology. This makes buntanetap a unique and promising therapeutic candidate for tackling cognitive decline across multiple neurodegenerative diseases.
Upcoming Presentation and Continued Research Focus
Annovis Bio will present the full biomarker data at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in December 2025. The company will provide additional details about the presentation closer to the event. This announcement is expected to further highlight the potential of buntanetap as a transformative therapy in the treatment of neurodegenerative diseases.
Based in Malvern, Pennsylvania, Annovis Bio remains committed to advancing its innovative therapies for Alzheimer’s and Parkinson’s diseases. With its growing clinical evidence, the company is positioning itself as a leader in the fight against these debilitating conditions. The recent stock surge reflects confidence in the company’s continued progress and its ability to deliver breakthrough treatments.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
